Last updated: August 7, 2026
Ziprasidone is a mature, genericized atypical antipsychotic with two principal dosage forms: oral capsules and intramuscular injection. The strongest commercial opportunities are formulation-led rather than molecule-led. Key targets include reducing the capsule’s food-dependent absorption, improving dose flexibility, developing orally disintegrating or multiparticulate products, and using cyclodextrin-based solubilization for differentiated injectable or concentrated presentations.
What excipients are used in ziprasidone capsules?
Ziprasidone capsules generally contain ziprasidone hydrochloride monohydrate with conventional solid-dose excipients. The branded Geodon capsule formulation identifies lactose monohydrate, pregelatinized starch, and magnesium stearate as core excipients. The capsule shell contains gelatin, titanium dioxide, and colorants that vary by strength (Pfizer, 2023).
| Formulation element |
Typical function |
Commercial relevance |
| Lactose monohydrate |
Diluent |
Low-cost bulk filler; may create suitability issues for lactose-intolerant patients |
| Pregelatinized starch |
Binder and disintegrant |
Supports capsule fill uniformity and drug release |
| Magnesium stearate |
Lubricant |
Controls manufacturing friction and ejection |
| Gelatin |
Capsule shell |
Standard hard-gelatin delivery system |
| Titanium dioxide and colorants |
Opacity and product identification |
Supports strength differentiation and branding |
The principal formulation problem is not capsule disintegration. It is exposure variability caused by food. Oral ziprasidone absorption increases substantially when administered with a meal, and the FDA label recommends administration with food. The label reports that systemic exposure is approximately doubled with food compared with fasting conditions under certain study conditions (FDA, 2023).
That food effect creates a direct excipient opportunity. A formulation that increases wetting, dissolution, supersaturation, or gastrointestinal solubilization could reduce the dependence on meal composition and timing.
How does food affect ziprasidone commercial performance?
Food dependence is the most commercially important biopharmaceutical attribute of oral ziprasidone.
Ziprasidone has limited aqueous solubility and high sensitivity to the fed or fasted state. Patients who take the medicine without a sufficient meal may receive lower exposure than intended. This creates adherence, counseling, and therapeutic-consistency problems.
Potential excipient approaches include:
- Surfactant-enhanced systems using polysorbates, sodium lauryl sulfate, or lipid-compatible surfactants.
- Lipid-based formulations using medium-chain triglycerides, mono- and diglycerides, or self-emulsifying drug-delivery systems.
- Polymer-based amorphous solid dispersions using polymers such as copovidone, hypromellose, or hypromellose acetate succinate.
- Cyclodextrin complexes using hydroxypropyl-beta-cyclodextrin or sulfobutyl ether-beta-cyclodextrin.
- Particle-size reduction through micronization or nanocrystal technology.
- Precipitation-inhibiting polymers that maintain supersaturation after gastrointestinal dilution.
The strongest product claim would not be "ziprasidone with a new excipient." It would be a measurable clinical or pharmacokinetic benefit, such as bioequivalence under fasting conditions, reduced variability across meal sizes, or equivalent exposure with a low-calorie meal.
What formulation patents could protect a new ziprasidone product?
A new ziprasidone formulation may be protected through composition, process, performance, and method-of-use claims.
Composition claims
Composition claims could cover:
- A defined ratio of ziprasidone to polymer.
- A specific surfactant or lipid system.
- A cyclodextrin complex.
- A nanoparticle or nanosuspension containing a stabilizer.
- A capsule containing a defined solid dispersion.
- A multilayer tablet or multiparticulate bead.
- A low-moisture formulation with a specified water activity.
Composition claims are commercially useful when the formulation requires a narrow excipient range. Broad claims covering routine excipients are more vulnerable to written-description, enablement, obviousness, and design-around challenges.
Performance claims
Performance-based claims may cover:
- Dissolution at a specified time point.
- Fed-to-fasted exposure ratios.
- Reduced pharmacokinetic variability.
- A particular Cmax or AUC range.
- Bioequivalence under fasting conditions.
- Stability after storage at elevated temperature and humidity.
Performance claims can create a stronger barrier if the formulation produces a clinically meaningful result that was not predictable from the prior art. They also create infringement questions that may require dissolution or pharmacokinetic testing.
Manufacturing claims
Manufacturing claims may cover:
- Spray drying.
- Hot-melt extrusion.
- Wet or dry granulation.
- High-pressure homogenization.
- Controlled precipitation.
- Solvent removal and residual-solvent limits.
- Specific particle-size distributions.
- A defined order of excipient addition.
Process claims are useful when the manufacturing route is difficult to replicate, but they usually provide narrower commercial protection than composition claims.
Method-of-use claims
Method-of-use opportunities include:
- Administration without a full meal.
- Administration with a defined low-calorie meal.
- Treatment of an indication with improved tolerability.
- Use in patients with swallowing difficulties.
- Use in patients requiring reduced food-related exposure variability.
- Pediatric administration through a dispersible dosage form.
Method claims face practical enforcement limits where the product label does not encourage the patented method or where prescribers use the product for multiple purposes.
What is the FDA regulatory status of ziprasidone?
Ziprasidone is an FDA-approved small-molecule antipsychotic marketed orally as capsules and parenterally as an intramuscular injection. The oral product is approved for schizophrenia and bipolar disorder indications. The injection is approved for acute agitation in adults with schizophrenia (FDA, 2023).
| Attribute |
Oral ziprasidone |
Intramuscular ziprasidone |
| Active ingredient |
Ziprasidone hydrochloride monohydrate |
Ziprasidone mesylate |
| Principal dosage form |
Hard gelatin capsule |
Single-dose vial for reconstitution |
| Key formulation issue |
Food-dependent absorption |
Aqueous solubility and injectable tolerability |
| Commercial pathway |
ANDA or 505(b)(2) |
ANDA or 505(b)(2), depending on product design |
| Biosimilar pathway |
Not applicable |
Not applicable |
| Main differentiation route |
Improved exposure consistency and adherence |
Longer stability, lower reconstitution burden, or alternative delivery |
A conventional generic capsule can generally pursue the ANDA pathway if it matches the reference listed drug in active ingredient, dosage form, strength, route, labeling requirements, and bioequivalence. A materially different dosage form or food-effect profile may require a 505(b)(2) application.
What is the Orange Book status of ziprasidone?
Ziprasidone’s core U.S. exclusivity has expired, and multiple generic manufacturers have entered the capsule market. The historical compound patent associated with ziprasidone is U.S. Patent No. 5,312,925, which covered benzisothiazolyl piperazine derivatives and reached the end of its effective U.S. term before generic competition expanded in the early 2010s (U.S. Patent and Trademark Office, 1994; FDA, 2024).
The practical Orange Book position is therefore different from that of a protected branded product:
- Core molecule protection is no longer a meaningful barrier.
- The commercial focus has shifted to manufacturing scale, supply reliability, bioequivalence, and formulation differentiation.
- Any active listed patents must be assessed at the product level and by dosage form.
- Method-of-use listings, if present, may not block all generic indications.
- A generic applicant may use a Paragraph IV certification against an unexpired listed patent or a Section viii statement to omit a protected indication.
Orange Book analysis should distinguish historical patents from currently enforceable listed claims. Patent status, pediatric exclusivity, and listed-use information can change by product and should be evaluated against the FDA’s current Orange Book data (FDA, 2024).
When did ziprasidone lose exclusivity?
Ziprasidone lost practical U.S. exclusivity in the early 2010s. FDA-approved generic ziprasidone capsules entered the market in 2012 following expiration of the principal compound patent and related regulatory protections. The exact competitive timing varied by strength, manufacturer, litigation outcome, and approval date.
| Milestone |
Approximate timing |
| FDA approval of Geodon capsules |
2001 |
| FDA approval of intramuscular Geodon |
2001 |
| Principal compound patent term end |
2012 |
| Generic capsule entry |
2012 onward |
| Current market position |
Mature generic market |
Geodon therefore has limited residual value as a conventional branded oral product. Value remains in differentiated formulations, hospital supply, contract manufacturing, and lifecycle products that solve the food-effect or administration problem.
Which companies are challenging or competing with ziprasidone?
Competition comes from both generic ziprasidone manufacturers and alternative atypical antipsychotics.
Generic ziprasidone competitors
Generic manufacturers have included large U.S. and international suppliers such as Teva, Dr. Reddy’s, Zydus, Lupin, and other ANDA holders. Market participation varies by strength, channel, shortage conditions, and contracting arrangements.
Therapeutic competitors
| Drug |
Competitive attribute |
Relevance to ziprasidone |
| Aripiprazole |
Broad oral and long-acting injectable franchise |
Strong alternative for maintenance treatment |
| Olanzapine |
High efficacy with metabolic liabilities |
Competes in schizophrenia and bipolar disorder |
| Quetiapine |
Extensive dosage-form and indication coverage |
Strong prescriber familiarity |
| Risperidone |
Oral and long-acting injectable products |
Competes in schizophrenia and bipolar disorder |
| Lurasidone |
Food requirement but differentiated positioning |
Directly competes in bipolar depression and schizophrenia |
| Asenapine |
Sublingual and transdermal options |
Competes where non-oral administration is valuable |
| Brexpiprazole |
Branded differentiation and adjunctive use |
Competes in selected treatment segments |
Ziprasidone’s advantages include relatively low generic pricing and a comparatively favorable metabolic profile versus some alternatives. Its disadvantages include QT prolongation concerns, the need for food with oral dosing, and limited long-acting injectable availability.
What injectable excipients are used in ziprasidone?
The marketed intramuscular product uses ziprasidone mesylate with sulfobutyl ether-beta-cyclodextrin sodium, commonly abbreviated SBECD. The cyclodextrin improves solubilization of the active ingredient for injectable administration (Pfizer, 2023).
| Injectable component |
Function |
| Ziprasidone mesylate |
Active pharmaceutical ingredient |
| SBECD |
Solubilizer and complexing agent |
| Sterile diluent after reconstitution |
Produces the injectable solution |
SBECD creates a differentiated excipient opportunity because it enables a practical injectable concentration without relying on aggressive cosolvent systems. Development constraints include excipient cost, renal safety assessment, vial fill volume, reconstitution time, and compatibility with container-closure systems.
Potential injectable commercial products include:
- A ready-to-use liquid presentation.
- A smaller-volume vial.
- A prefilled syringe, subject to stability and device requirements.
- A longer-stability formulation for emergency departments.
- A concentrated formulation with reduced reconstitution steps.
- An alternative cyclodextrin or cosolvent system.
A ready-to-use product could improve hospital workflow, but its commercial value would depend on stability, preservative strategy, device compatibility, and whether the product receives meaningful purchasing preference.
What commercial opportunities exist for ziprasidone excipients?
Food-effect reduction
This is the highest-value oral opportunity. A product that maintains exposure when taken fasting could address a labeled administration limitation. The developer would need robust fed and fasted pharmacokinetic data, comparative dissolution, and a label that communicates the differentiated use.
Orally disintegrating ziprasidone
An orally disintegrating tablet could target patients with dysphagia, psychiatric illness-related nonadherence, or supervised administration needs. Excipients may include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, and taste-masking agents.
The central technical issue is taste. Ziprasidone’s bitter or unpleasant sensory profile may require polymer coating, ion-exchange complexation, lipid masking, or encapsulated microparticles.
Sprinkle or multiparticulate capsules
Multiparticulate products could provide dose flexibility and easier administration. Potential systems include coated pellets, mini-tablets, or drug-loaded granules. The main risks are dose uniformity, food interaction changes, and accidental crushing or chewing of modified particles.
Pediatric and geriatric products
A liquid, dispersible, or low-dose product could address populations poorly served by standard capsules. Such products may require a 505(b)(2) strategy if the dosage form, dosing instructions, or pharmacokinetic profile differs materially from the reference product.
Hospital-focused injectable products
The injection market offers lower volume than chronic oral therapy but may support premium pricing if a new presentation reduces preparation time or medication errors. The strongest value proposition is operational efficiency rather than a new therapeutic mechanism.
How strong is the ziprasidone patent estate?
The legacy estate is weak as a barrier to conventional generic entry because the principal compound protection expired and generic capsules are established. A new estate could still be commercially meaningful if it protects a formulation that:
- Solves the food-effect problem.
- Requires a non-obvious excipient combination.
- Produces a defined pharmacokinetic improvement.
- Has a difficult-to-replicate manufacturing process.
- Is supported by a differentiated FDA label.
- Can be enforced through product testing or ANDA litigation.
A formulation patent is more valuable when it combines composition claims with process and performance claims. A single narrow excipient claim is easier to design around.
What generic entry risks exist for a new ziprasidone formulation?
A new formulation faces four principal risks.
First, a generic manufacturer may reproduce the same clinical objective through a different excipient system. Second, the FDA may determine that the proposed product can use the ANDA pathway, reducing regulatory differentiation. Third, bioequivalence may be difficult to demonstrate if food conditions create high pharmacokinetic variability. Fourth, payer substitution may limit the price premium over inexpensive generic capsules.
A 505(b)(2) product can obtain approval for a differentiated dosage form, but patent protection does not guarantee commercial uptake. The product must improve adherence, administration, hospital efficiency, or exposure consistency enough to justify formulary and payer adoption.
What is the revenue exposure for branded ziprasidone?
Branded Geodon revenue is structurally exposed to generic substitution because the product has no meaningful molecule-level exclusivity. Chronic oral sales are particularly vulnerable to low-cost generic competition. Injectable sales may retain greater commercial value in institutional settings because hospitals purchase on availability, contracting, preparation convenience, and supply continuity.
The most defensible revenue opportunities are:
- A food-effect-reduced oral product with a clear label advantage.
- An orally disintegrating or taste-masked dosage form.
- A hospital-ready injectable presentation.
- Contract development and manufacturing of ziprasidone formulations.
- Regional licensing of formulation patents in markets where generic penetration is lower.
Key Takeaways
- Ziprasidone is a mature genericized molecule with limited value from conventional capsule commercialization.
- The main oral formulation problem is food-dependent absorption.
- Excipient strategies should prioritize solubilization, supersaturation control, lipid delivery, amorphous solid dispersion, and particle engineering.
- The branded capsule uses standard excipients, while the injection relies on SBECD for solubilization.
- A new formulation may qualify for ANDA or 505(b)(2) approval depending on how substantially it differs from the reference product.
- The strongest patent opportunity is a formulation supported by pharmacokinetic, dissolution, and clinical-use data.
- Biosimilar risk is irrelevant because ziprasidone is a small molecule, not a biologic.
- Hospital injectable products may support better margins than conventional oral capsules.
- Generic entry risk remains high unless a new product obtains a meaningful administration, exposure, or workflow advantage.
FAQs
Can ziprasidone be formulated without lactose?
Yes. A lactose-free capsule or tablet could use mannitol, microcrystalline cellulose, dicalcium phosphate, or other fillers. The product would still require formulation development, stability testing, and bioequivalence evaluation.
Is ziprasidone suitable for an orally disintegrating tablet?
Potentially. The principal development issue is taste masking, followed by control of disintegration, dose uniformity, and food-related pharmacokinetics.
Can SBECD be replaced in injectable ziprasidone?
Potentially, but the replacement must provide adequate solubility, stability, tolerability, and injectable compatibility. A substitute could create a new formulation patent position if it delivers a non-obvious technical benefit.
Would a fasted-state ziprasidone formulation receive a new patent?
It could, if the formulation and resulting pharmacokinetic performance satisfy novelty and non-obviousness requirements. The commercial strength would depend on claim breadth and the ability to prove infringement.
Does ziprasidone have biosimilar competition?
No. Ziprasidone is a chemically synthesized small molecule. Competition proceeds through generic drug applications rather than the FDA biosimilar pathway.
References
-
Food and Drug Administration. (2023). Geodon (ziprasidone hydrochloride) capsules and ziprasidone mesylate injection prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Pfizer Inc. (2023). Geodon product labeling. Pfizer.
-
U.S. Patent and Trademark Office. (1994). U.S. Patent No. 5,312,925: Benzisothiazolyl piperazine derivatives. U.S. Department of Commerce.
